Relapsed blood cancer occurs when leukemia, lymphoma, or myeloma returns after initial remission, requiring specialized treatment pathways that differ fundamentally from first-line therapy based on disease biology, prior treatment response, transplant eligibility, and overall fitness. TL;DR Treatment resistance affects 30-40% of blood cancer patients, but salvage chemotherapy, targeted therapy, immunotherapy, stem cell transplant, and CAR-T therapy provide established pathway

Leukemia relapse after chemotherapy affects approximately 40-50% of younger adults and the majority of elderly patients with acute myeloid leukemia, but multiple effective treatment pathways now exist including salvage chemotherapy, targeted therapy, CAR-T cell therapy, and stem cell transplantation. TL;DR Yes, treatment is available when leukemia relapses after chemotherapy, with options including salvage chemotherapy, targeted therapy, CAR-T cell therapy, and stem cell tran